- Home
- OIA vs AVIR Comparison
OIA vs AVIR Comparison
Compare OIA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
N/A
Current Price
$5.27
Company Overview
Basic Information| Metric | OIA | AVIR |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.8M | 429.1M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OIA | AVIR |
|---|---|---|
| Price | $5.96 | $5.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 94.3K | ★ 212.0K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.87 | $2.78 |
| 52 Week High | $6.40 | $6.45 |
Technical Indicators
Market Signals| Indicator | OIA | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 47.87 |
| Support Level | N/A | $5.13 |
| Resistance Level | $6.23 | $5.73 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 1.61 | 2.27 |
Price Performance
Historical Comparison OIA
AVIR
About OIA Invesco Municipal Income Opportunities Trust
Invesco Municipal Income Opportunities Trust is a closed-end management investment company. The Trust's investment objective is to provide a high level of current income which is exempt from federal income tax.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.